The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
 
Ryan Leibrandt
No Relationships to Disclose
 
Paul Henry Frankel
Stock and Other Ownership Interests - Asensus Surgical; Geron
Consulting or Advisory Role - Johnson & Johnson/Janssen
Other Relationship - FlexSim
 
Jan Hendrik Beumer
Employment - Voisin Consulting (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - GNS Healthcare
Research Funding - Abbvie (Inst); Spectrum Pharmaceuticals (Inst); TriSalus Life Sciences (Inst)
Patents, Royalties, Other Intellectual Property - Sulphoraphane for melanoma chemoprevention (Inst)
Expert Testimony - Pfizer; Spectrum Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Qrono
 
Naoko Takebe
No Relationships to Disclose
 
Ming Yin
Stock and Other Ownership Interests - Novavax
 
Hamid Emamekhoo
Consulting or Advisory Role - Cardinal Health; Exelixis; Seagen; Seagen
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)
 
Steven Gore
No Relationships to Disclose
 
Mamta Parikh
Consulting or Advisory Role - AstraZeneca; Exelixis; OncoCyte; Seagen
Research Funding - Karyopharm Therapeutics